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Four patients with severe combined immunodefi ciency showed adverse reactions to BCG. Patient M.K. had mild infl ammation at the site of the BCG injection and was successfully treated with rifampin. The patient subsequently received a bone marrow transplant, and 2 months later poor appetite, failure to thrive, and subfebrile condition were noted. Disseminated skin changes (with pus formation in the subcutaneous layer), osteomyelitis, and multiple lesions in the liver were found. A skin biopsy showed tuberculoma formations, which were PCR-positive for Mycobacterium tuberculosis complex (Amplifi ed Myco- There are at least 3 subtypes that display a 100% similarity.
bacterium Tuberculosis Direct [MTD]
Test, Gen-Probe, Inc., San Diego, CA, USA) but had negative culture results. Complete recovery, including full immunologic reconstitution, was reached after 12 months of treatment with triple antituberculosis (TB) therapy (rifampin, isoniazid, and ciprofl oxacin). Patient M.C., a 6-month-old boy, was admitted to an intensive care unit because of respiratory insuffi ciency. An unhealed BCG vaccination site was noted. Bronchopulmonary lavage samples were tested for M. bovis; positive PCR and culture results led to the diagnosis of disseminated BCG infection. Despite intensive anti-TB therapy, the child died of multiple organ failure. Autopsy showed typical granuloma formations and a hypoplastic thymus, typical for severe combined immunodefi ciency. Male patients S.D. and C.G. were admitted to intensive care units at 6 and 8 months of age, respectively, with lymphadenopathy and multiple organ insuffi ciency. Each boy died of multiple organ failure; postmortem examination found granuloma formation and a hypoplastic thymus in each (8) .
Eight patients with severe combined immunodefi ciency had local adverse events after vaccination with BCG. Infl ammation at the vaccination site was observed for all 8. For all except 1, dual anti-TB therapy (rifampin, isoniazid) or monotherapy was successful. For 1 of these patients, anti-TB treatment was stopped 3 months after bone marrow transplant, but increasing infl ammation and lymphadenitis appeared 1 month later, with positive PCR and negative culture results for Mycobacterium spp. After 12 months of triple anti-TB therapy, this patient fully recovered.
In 2-month-old female patient, W.M., who had interferon-γ-receptor defi ciency, axillary lymphadenopathy with normal healing of the vaccination site was noted 7 weeks after BCG vaccination. Tuberculous lymphadenitis was diagnosed by histopathologic methods. Despite dual anti-TB therapy and streptomycin administration, the girl died. At autopsy, multiple tuberculous granulomas were found (5).
In 4-month-old female patient M.K., who had interleukin-12-receptor defi ciency, axillary lymphadenopathy with positive results from Mycobacterium typing was noted. Dual anti-TB therapy for 12 months produced good results.
In 7-month-old female patient B.B., who also had interleukin-12-receptor defi ciency, axillary lymphadenopathy was noted. Mycobacteria PCR-positive for the M. tuberculosis complex were found in the purulent secretion. Despite dual anti-TB therapy, the patient experienced 2 episodes of relapse. After another 2 years of anti-TB therapy, disseminated BCG infection, with pulmonary consequences, developed.
In patient R.C., a 6-month-old boy, osteomyelitis was diagnosed, and delayed healing of the BCG vaccination scar was noted. Investigation of his immunologic status showed no abnormalities. However, because granulomatous infl ammation was present in a bone biopsy sample and staining for BCG produced a positive result, triple anti-TB therapy was provided for 12 months, with good results.
The literature describes >200 cases of disseminated BCG infection in patients with primary immunodeficiency (1-7) . The diagnostic diffi culties described for 8 of our patients with primary immunodefi ciency have been noted by others (1-6,8-10 ). In only 2 cases was the Mycobacterium species successfully isolated and identifi ed as the M. bovis BCG strain. We propose novel criteria for the diagnosis of disseminated BCG infection in persons with primary immunodeficiency (Table) . These criteria have recently been submitted to the European Society for Immunodefi ciencies. Severe, long-term inflammation with granuloma formation in patient with primary immunodeficiency *Male or female patient with or without genetic confirmation of severe combined immunodeficiency, interferon-γ-receptor deficiency, interleukin-12-receptor deficiency, or other primary immunodeficiency. †Areas of involvement may include lymph nodes, skin, soft tissues, lungs, spleen, liver, bones.
We believe that patients with severe combined immunodefi ciency and any form of mild local changes at the BCG injection site should be given single or double anti-TB therapy, which should be continued until complete immunologic reconstitution occurs after bone marrow transplant. Severe local BCG infection with regional lymph node involvement needs at least triple anti-TB therapy followed by long-term prophylaxis. Disseminated BCG infection needs anti-TB therapy, including >4 anti-TB drugs, until the patient fully recovers.
